QUMAS, the leading provider of compliance solutions to highly regulated companies, has announced that MannKind Corporation has selected the QUMAS Biotechnology Package (based on the industry leading eDMS QUMAS DocCompliance) to improve document control and to reduce approval lifecycles of documents in a compliant environment.
With this package, MannKind is gaining access to a world class document management solution, packaged to ensure low acquisition and implementation costs while harnessing the strong functionality of DocCompliance.
MannKind Corporation chose QUMAS because it demonstrated the deepest understanding of MannKind's requirements, robust functional capabilities, and also brings the most experience in executing projects of this nature and scope.
The experience of QUMAS staff and the configurability of the solution mean that MannKind will be able to deploy the Biotech Package very quickly, ensuring ease of adoption and fast track training. The scalable nature of the solution guarantees that it will meet the organizational needs as MannKind continues to grow. Future plans include deploying DocCompliance across the enterprise to include quality, legal, marketing, human resources and finance.
‘We needed to retire our legacy document management system and were in the market for not just a next generation, flexible system but also for a simple and elegant architecture from a company that had done this many times over and could lead us through this project,’ said Mark Sander, vice president of information technology at MannKind Corporation.
‘We found QUMAS' compliance solutions to be very mature and on a strong technical platform and our conversations with QUMAS customers convinced us of QUMAS' ability to make our project a success.’
‘We are very pleased to add MannKind Corporation to our customer community,’ said Sefton Cohen, vice president of global sales at QUMAS. ‘Our goal is to ensure that all growing biotechs not only have access to a leading eDMS which is currently in use in more than 250 facilities globally, but to ensure the industry can leverage the QUMAS compliance expertise, as configured in the system, to ensure a compliant organisation from the outset, making biotechs more viable in a regulatory context and more attractive to investors and partners.’
